PAH drug switch under the microscope: will patients fare better?
NCT ID NCT07013149
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study looks at what happens when people with pulmonary arterial hypertension (PAH) switch from one medication (ambrisentan) to another (bosentan). Researchers will track 121 adults over 3-6 months to see if their risk scores, symptoms, and lab results change. The goal is to provide real-world data to help doctors make better treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION PAH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
InCor - FMUSP
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.